



# Multi Annual Strategy

2024 - 2028

NLR is an alliance of six NGOs in India, Indonesia, Brazil, Mozambique, Nepal (where 85% of leprosy patients live) and the Netherlands. The international office in the Netherlands supports the alliance with knowledge, funding and leading multi-country projects.



- 220 staff
- An alliance of 6 NGO's
- €12 million budget
- 55 years experience

We have over 55 years of experience. Much has been achieved in the fight against leprosy due to new treatments. The number of new leprosy patients has remained stable around 200,000 for many years. Leprosy is not only curable, but now also preventable. With new innovations, treatment and interventions we believe we can achieve zero leprosy (no new leprosy patients) by 2040. We are the generation to beat leprosy and make this ancient disease truly part of the past.

## We are NLR

- NLR offices
- Additional areas of activities



### We started with a dream

Since 1967, NLR has strived to make leprosy a disease of the past.



### Much has been achieved

In the 1960s, around three million leprosy patients worldwide were facing lifelong treatment.

Now, around 200,000 new leprosy patients are detected each year around the globe.



### Vision and Mission

**Our Vision:** A world free of leprosy and its consequences

**Our Mission:** to prevent, detect, and treat leprosy, and to support the health, ability, and full inclusion in society for persons affected by leprosy.



### Zero leprosy by 2040


NLR's overall goal is zero leprosy by 2040, after 4,000 years, we are the generation that can end one of the world's oldest and most notorious diseases

# Game-changing solutions: New preventive treatment



We have reached a critical time in the fight against leprosy. The World Health Organization has identified leprosy as one of the three neglected tropical diseases that can be eliminated in the near future. To achieve that, preventive treatment such as SDR-PEP is key.

SDR-PEP is a single dose of the antibiotic rifampicin as a postexposure prophylaxis given to contacts of a person diagnosed with leprosy, such as family members, neighbours and friends. This medication is recommended by the World Health Organisation. Research shows that to reduce the incidence of leprosy by 90% over the next 22 years, the cumulative number of people requiring preventive treatment is projected at 40 million. SDR-PEP reduces the risk of developing leprosy by 60%. If better treatment becomes available and is widely implemented, the number of years to achieve zero leprosy will decrease. NLR is working on an enhanced regimen, PEP++, that is expected to be 80-90% effective.



## Our strengths

- 55 years track record in evidence-based programmes
- Strong reputation and leading partner in many national and international networks and partnerships
- Technical leprosy expertise combined with programmatic know-how
- Development and implementation of innovative approaches (PEP, PEP++)
- Stable funding from 46,500 loyal donors in the Netherlands and international institutional funders

## Our Strategic Goals

### Zero leprosy by 2040

50% decrease of annual new leprosy patients detected in NLR countries

#### Impact Goals

National governments accelerate the elimination of leprosy

Prevention of leprosy is scaled up supported by PEP services

Persons affected by leprosy enjoy equal rights and opportunities



Research & Innovation



Advocacy & Technical Support



Learning & Development

#### Strategic foundation

A solid funding base, relevant visibility and strong reputation

A strong alliance through national leadership and international support

NLR: Brazil, India, Indonesia, Mozambique, Nepal and the Netherlands

- In eight years, 120 countries are estimated to report no new leprosy patients
- NLR wishes to contribute a 50% decrease in annual new leprosy patients in NLR alliance countries (compared to 2021)
- Achieving our ambitious goals depends on strong collaboration with WHO, governments, donors, partners and colleagues.
- NLR has developed a new and very effective tool: one dose of the antibiotic rifampicin. By scaling up this innovation, we can break the chain of infection and prevent leprosy, disabilities, stigma and social exclusion.

Help us achieve our dream: **A world without leprosy in 2040**

For more information visit: [www.nlrinternational.org](http://www.nlrinternational.org)

Contact us for advice about and collaboration on: Preventive (PEP) services for leprosy, leprosy elimination monitoring tool (LEMT), preventive treatment training and research materials: [info@nlrinternational.org](mailto:info@nlrinternational.org)

until  
**No Leprosy Remains**